Compare General Mills, Inc. (GIS) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Heron Therapeutics Inc — how do they compare? General Mills, Inc. trades at $32.07 (market cap $17.43B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: General Mills, Inc. is far larger — about 256.3× Heron Therapeutics Inc's market cap, and General Mills, Inc. pays a 7.49% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Heron Therapeutics Inc for 35 Days on average.
| GIS | HRTX | |
|---|---|---|
Market Cap | $17.43B | $68.01M |
Volume | 16,554,362 | 1,891,941 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $1.49 |
52-Week Low | $31.67 | $0.27 |
Typical Hold Time | 106 Days | 35 Days |
Enterprise Value | $30.61B | $174.75M |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.77, down 1.27% with bearish technical signals despite beating Q2 2026 EPS estimates. The stock shows attractive valuation metrics with P/E of 9.23 and P/S of 0.96, but faces fundamental challenges including negative net income margin of -4.89% and declining revenue trends from $19.5B in 2025 to projected $18.3B in 2026. Recent CEO transition to Dana McNabb and dividend stability at $0.61 quarterly provide some stability amid operational headwinds.
The outlook remains cautious with Wall Street showing mixed sentiment - 61% hold ratings but $36 consensus target suggests 13% upside. Key risks include ongoing margin pressure, competitive threats in packaged foods, and macroeconomic sensitivity. The high 7% dividend yield offers income appeal but sustainability concerns persist given negative profitability metrics and cash flow challenges.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
